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Abstract
Contrast agents (CAs) are small molecules used in magnetic resonance imaging (MRI) to
help diagnose various forms of cancer. While MRI is advantageous over other clinical imaging
techniques, limitations of today’s contrast agents containing gadolinium (Gd) hinder their safety,
sensitivity, and specificity. The conventional CAs that MRI relies on are considered low-relaxivity
and are not optimally effective at enhancing MR signal. Additionally, they lack cell-specificity and
circulate throughout the body. Furthermore, unbound Gd3+ is nephrogenic which prevents its use
in patients with impaired renal function. In the clinic, these limitations mean high dosages of these
compounds must be administered to patients in order to produce an image that struggles to
highlight the exact tumor location. Our aim was to improve conventional CAs by synthesizing a
high-relaxivity (HR) targeted contrast agent (HR-TCA). The cell-specific nature of the HR-TCA
will allow for its accumulation at tumor sites while the HR will produce a stronger MR signal per
molecule of CA. Combined, this means a much lower and therefore safer dose of CA can be used
to produce an image of the exact tumor location with superior contrast. Our modular approach
allows us to easily combine this HR contrast agent (HR-CA) to any targeting peptide using a linker
in a convergent, one-step synthesis. Our synthetic approach for the HR-CA module attaches a
macrocyclic chelator, DO3A, to the side chain of an orthogonally protected alanine. This is a
modification to the approach published by Boros in which t-butyl groups were utilized to protect
DO3A. In our modular approach, Gd is chelated early to protect the acetic acid donor arms of
DO3A from participating in unwanted side reactions for the remainder of the synthesis,
eliminating any need to expose the final HR-TCA to the harsh acidic conditions of TFA that are
necessary to remove t-butyl protecting groups. Upon removal of the N- and C-terminal protecting
groups, the HR-CA module is coupled directly to our in-house synthesized targeting module which
is comprised of the targeting agent (DCL) and linker (DSS) already attached to afford the final HRTCA. T1 relaxation measurements of relevant intermediates and the final product were performed
to compare their relaxivities with those of commercial CAs used in clinics, labs, and hospitals
today. Although the HR-CA and final HR-TCA exhibited only a modest increase in T1 relaxivity
compared to commercial CA Gd-DOTA, in a striking discovery it was observed that the presence
of both a tryptophan spacer and an Fmoc protecting group boosted the T1 relaxivity significantly.
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Frequently Used Solvents
ACN Acetonitrile
AmAc Ammonium Acetate
DCM Dichloromethane
DiH2O Deionized Water, 18mΩ
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Introduction
Background: Cancer
Despite breakthroughs in modern medicine such as chemotherapy, radiation therapy, and
the development of molecular imaging, cancer persists as one of the leading causes of death
worldwide. In 2016, it was the leading cause of death for individuals between the ages of 30 and 69
throughout 50 countries around the world.1 After heart disease, it was the leading cause of death in
2017 claiming 599,108 lives.2 According to the CDC, prostate cancer (PCa) is the second leading
cause of cancer death in American men. It is estimated that 1 in 8 men will be diagnosed with PCa
sometime in their lifetime, and 1 in 41 men will die from it.3,4 Although our understanding of
cancer and cancer treatments are always improving, the number of new global cancer cases per
year is expected to reach 23.6 million by 2030. 5 Additionally, the number of US cancer cases is
predicted to increase to over 2.2 million, or 49%, by 2050. 6 For these reasons, efforts to develop
safer and more effective cancer treatments must continue.
Cancer most often starts localized in a single cell due to an error in a region of DNA called
a tumor-suppressor or proto-onco gene. These genes are integral parts of the biological machinery
that regulate the cell cycle and cellular growth. While DNA is commonly thought of as the
blueprint of life, it also functions as a regulatory system for all the different cellular processes
needed to help keep the body healthy. Another way by which cancer can begin is with
inappropriate signaling of the proteins and protein complexes that regulate cell growth; Ensuring
that these biological processes are properly maintained is critical in preventing the onset and
advancement of cancer. Loss of control of the cell cycle can quickly lead to unregulated cell growth
and ultimately the start of a tumor.7–10
Some types of tumors (such as moles) are harmless, only growing to a certain size and can
easily be removed if desired. However, if the tumor is malignant, it can continue growing to the
point where it interferes with the body’s major organs and hinders their function. Once a malignant
tumor has established itself in the body, it can easily catch a ride throughout one of the body’s
main highways (the lymphatic and circulatory systems) and metastasize. It is for this reason that
early detection and treatment are important to improve patient outcomes. If a malignant tumor is
not detected in a timely manner, it has a much higher chance of metastasizing and causing more
damage than what chemotherapy, radiotherapy, and surgical procedures can treat. 11,12
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Molecular Imaging and MRI in Cancer Treatment
In aggressive cancers that can grow and spread rapidly throughout the body, it is important
to obtain a diagnosis as soon as possible. The earlier the tumor is detected, the greater a chance it
stays localized and will be easier to remove with surgery or treated with chemotherapy or targeted
radiation. There are many non-invasive imaging methods such as x-ray imaging, computed
tomography (CT), positron emission tomography (PET), MRI, and ultrasound imaging that can be
used by medical professionals for the detection and diagnosis of all kinds of cancers. 13 With any
imaging method, the images produced should be of the highest clarity and resolution possible in
order to allow physicians to distinguish the boundaries of malignant tumors and their locations
within the body. To accomplish this, molecular probes are often used to highlight cancerous cells
and better differentiate them from healthy tissue, improving image quality and further assisting in
assessing tumor location and metastasis. Unfortunately, detecting cancer in its early stages is often
challenging due to the difficulty in distinguishing cancerous cells from healthy tissue.
Detecting cancer, especially in its early stages, is not an easy task. The initial signs of
abnormal cell growth preceding the onset of cancer start genetically and primarily affect the tumor
microenvironment. This microenvironment is a complex network of tissue and signaling molecules
which includes the extracellular matrix, nearby healthy cells, cytokine signaling networks, growth
factors, and proteases that control autocrine and paracrine intercellular communication.14 These
initial changes do not always produce a deformation in the body that is readily-observable using
current

clinical

imaging

techniques. 15,16

Through

changes

facilitated

by

the

tumor

microenvironment, a cell can gain the ability to evade apoptosis, become insensitive to anti-growth
signals, sustain angiogenesis, and replicate indefinitely.15
While the cells may start out as a small adenoma, they can remain undetectable to the
individual for years but later advance to an observable hyperplasia or dysplasia, an enlargement of
a tissue due to abnormally high cell growth and replication. If undetected, these cells become
increasingly malignant and the progression of the disease is much more likely to accelerate faster
than what chemotherapy and radiation therapy can effectively treat. 12,15 The earlier a tumor is
detected, the greater of a chance it is still localized and will be easier to remove with surgery or
treated with chemotherapy or targeted radiation.
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Biomarkers and Receptors: Molecular Targeting
A multitude of proteins and protein complexes work together nonstop to maintain healthy
cell function. They can be localized to the plasma membrane, released outside of the cell for
circulation, or exist intracellularly. In diseased cells, the behavior of these proteins, their
expression, and even their 3-dimensional structures can deviate significantly from what is
considered healthy. Thus, these kinds of changes in a protein or other biomolecule can be
associated and correlated with the initiation, progression, and advancement of cancer.
Recent research has sought to improve the effectiveness of CAs by designing them to bind
to proteins that are associated either with specific cell types or specific regions of the body.
Targeting an imaging agent to a biomarker enables it to accumulate at a specific site in the body
which concentrates and increases the signal at the region of interest without making any
modifications to the molecular structure of the imaging agent itself. This is a common strategy in
molecular imaging that is already used in many imaging applications today. For example, serum
albumin, the most abundant blood plasma protein, is present in blood serum at concentrations of
500-700 μM and can be targeted for blood vessel imaging with the contrast agent Vasovist. (Fig. 1)
Similarly, fibrin can be targeted to image thrombosis and uncontrolled clotting. 13,16

Figure 1: (Above) Structure of serum albumin targeted contrast agent, Vasovist. (Used with permission from
Werner et al.)

Different cancers can also have biomarkers that are specific to their particular cell type. For
example, breast cancer cells have the potential to overexpress up to three different types of cell
membrane receptors: estrogen receptors, progesterone receptors, and human epidermal growth
factor 2.17 Similarly, the discovery of the Prostate-Specific Membrane Antigen (PSMA) as a
biomarker provided a means by which PCa could be targeted for improved imaging and
monitoring of the disease.
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Prostate-Specific Membrane Antigen Receptor
PSMA, also known as Glutamate Carboxypeptidase II (GCPII), is a homodimeric,
transmembrane zinc-dependent exopeptidase. In other words, it consists of two monomers (Fig. 2)
that are anchored into the lipid bilayer of cells, and it uses zinc ions to cleave terminal peptide
bonds. Only the extracellular portion of PSMA can be modeled because its transmembrane
portion is incompatible with crystallization techniques. 18,19

Figure 2: (Above) The two subunits of PSMA. Diagram made in-house. The model of PSMA was imported
into molecular visualization program UCSF ChimeraX from the Protein Data Bank (PDB) using PDB ID:
1Z8L. The 3D structure was elucidated by Davis et al. from the X-ray diffraction pattern of crystallized
human PSMA.20 Used with permission.

PSMA can be found in several healthy cell types where its physiological role is tissue
dependent. In addition to the secretory acinar epithelium of prostate cells, it can also be found in
astrocytes (abundant glial cells of the brain) and Schwann cells (myelin-sheathed cells of the
parasympathetic nervous system) where it performs synaptic hydrolysis of N-acetyl-aspartyl-Lglutamic acid (NAAG) to generate the neurotransmitter glutamate.18,19 (Fig. 3) Additionally, it acts as
a folate hydrolase in the small intestine to assist the dietary absorption of folate.21

4

Figure 3: Hydrolysis of N-acetyl-aspartyl-L-glutamic acid by PSMA.

Domains, Active Site, and Mechanism of PSMA
Each subunit of PSMA has three domains: an apical domain, protease domain, and Cterminal domain. (Fig. 4) The two dimers are held together by interactions between the C-terminal
domain of one monomer, and the apical and protease domains of the other monomer. 19

Figure 4: Domains of PSMA. Diagram made inhouse. The 3D model of PSMA was imported
into molecular visualization program UCSF
ChimeraX from PDB ID: 1Z8L. The 3D
structure was elucidated by Davis et al. from the
X-ray diffraction pattern of crystallized human
PSMA. Used with permission.20

Figure 5: Active sites of the PSMA receptor.
Diagram made in-house. The 3D model of
PSMA was imported into molecular visualization
program UCSF ChimeraX from PDB ID: 1Z8L.
The 3D structure was elucidated by Davis et al.
from the X-ray diffraction pattern of crystallized
human PSMA. Used with permission. 20

PSMA has two active sites, one in each of its two protease domains, that face in opposite
directions. (Fig. 5) Inside each active site is a catalytic glutamate that transfers protons between the
nucleophile and scissile amide nitrogen, a nucleophile in the form of a hydroxide ion, and two Zn2+
ions which help stabilize the transition state of the substrate during the reaction.

5

The elucidation of the 3D structure of PSMA (and therefore the active site) allowed for the
catalytic mechanism to be discovered. (Fig. 6) Once the substrate enters and is bound inside the
active site, the carbonyl of the peptide bond is polarized through its interactions with the Zn2+ ions
(circled in red). This induces the hydroxide nucleophile to perform a nucleophilic attack on the
amide carbonyl (boxed in orange). The resulting tetrahedral intermediate is then stabilized by the
Zn2+ ions (boxed in yellow). Finally, the glutamic acid extracts the proton from the hydroxide and
shuttles it to the amide nitrogen, causing cleavage of the peptide bond and generating the two
products (boxed in green).18 Understanding this mechanism has enabled the design of inhibitory
molecules that can be used to target PSMA. This is a frequently used strategy in molecular
imaging: Once a biomarker is found, inhibitors can be designed based on the active site, and the
specific binding of the inhibitor to the active site can be used to target cancer.

Figure 6: Catalytic mechanism of PSMA.18 Used with permission from Pavlícek et al.

Targeting PCa with DCL
As an inhibitor with specific binding, DCL can also be used as a targeting group. Inhibitors
of PSMA can be classified as either substrate or transition state analogs of NAAG. Figure 7 shows
a comparison between the NAAG substrate (A), inhibitors which mimic the peptide bond (B), and
inhibitors which mimic the transition state of the catalytic mechanism (C). The DCL inhibitor (Fig.
8) is based on the Glu-Lys dipeptide which mimics the peptide bond. The two residues are joined
6

together by a urea motif that effectively replaces the peptide bond and prevents its cleavage from
taking place.20,22 PSMA recognizes DCL using its “glutarate sensor”, a group of amino acids near the
active site consisting of Tyr552, Arg210, and Asn257. In particular, Tyr552 interacts with the αcarboxylic acid (Fig. 8, pink) while Arg210 interacts with the γ-carboxylate.22 (Fig. 8, blue)

Figure 7: (Above) Structure of NAAG (A) compared to structure of PSMA inhibitors that mimic either the
peptide bond using a urea motif (B), or phosphonate/phosphoamidate that mimics the transition state of the
substrate (C).

Figure 8: (Above) Structure of DCL of compound 10 with the two portions that PSMA uses for substrate
recognition highlighted in pink and blue. The bond that PSMA attempts to cleave is highlighted in red.

While we unfortunately did not have the means to evaluate the relaxivity of these novel
compounds in vivo, we have previously used confocal microscopy (CFM) to show the efficacy of
our targeting group, DCL, to selectively bind to overexpressed PSMA receptors in C42 cells using
a near-infrared fluorescent dye, Cy5.5, attached to a lysine side chain. (Fig. 9) DCL was shown to
have minimal binding to PC3 cells (Fig. 10, right) which have normal PSMA expression while
overwhelmingly binding to C42 cells (Fig. 10, left and middle) which overexpress the PSMA
receptor.

7

Figure 9: (Above) Structure of our previously reported DCL-DSS-Lys(Cy5.5) TMIA for confocal
microscopy (CFM).

Figure 10: (Above) CFM images of previously reported DCL-DSS-Lys(Cy5.5) TMIA. Images obtained at
RIT in Dr. Irene Evans' lab. (Hanafish, A.; Embong, A.; Walden, R.; Anderson, T.; Schmitthenner, H.;
Evans, I. (2016, Jan). Targeted molecular imaging agents (TMIAs) for improved detection of cancers.
Molecular Biology of the Cell.; American Society of Cell Biology (Vol. 27)).

Significance of PSMA
PSMA is heavily involved in the progression of PCa. PCa cells can overexpress PSMA up
to 1000-fold compared to healthy cells, enabling for its use as a biomarker. PSMA can also be
used as a prognosis indicator, as the amount of overexpression directly correlates with disease
progression. High PSMA expression is also associated with a higher risk of recurrence, even after a
patient has undergone curative surgery. In addition to its abundance in PCa cells, it can also be
found overexpressed in the neovasculature of other solid tumors, thus expanding its potential
applications beyond those of just PCa.22 Even though there are various imaging methods that can
be used to image cancerous cells, MRI has many advantages over other modalities.

8

Background: Magnetic Resonance Imaging
Since its first use in the medical field in the late 1970’s, MRI has played a central role in
many successful patient outcomes across the globe.23,24 MRI is advantageous over all other imaging
techniques. It can produce much higher resolution images compared to the fuzzy and blurry
images of other imaging modalities such as PET. Furthermore, MRI can generate 3D images with
sub-millimeter spatial resolution, and its ability to image deep into soft tissues makes it effective in
whole-body detection of metastasis. Unlike PET and CT scans, MRI does not require the use of
harmful ionizing radiation which can contribute to a patient’s overall long-term cumulative
radiation exposure which in itself is associated with an increased risk of cancer.13,16,25 Additionally,
MRI is also capable of assessing physiological characteristics such as vascularization, oxygenation,
and diffusion.12,16

MRI Scanners
MRI is an imaging technique based on nuclear magnetic resonance (NMR) which
distinguishes different regions of the body from one another based on differences in the magnetic
and physical properties of water in different tissues. All NMR instruments share five core
components: 1.) a strong electromagnet that produces a homogenous magnetic field (termed B 0);
2.) a radiofrequency (RF) transmitter that produces electromagnetic radiation; 3.) a RF receiver
that detects signals from resonating nuclei; 4.) a console that controls the RF pulses and converts
the signals into a digital format; and 5.) software to interpret the data produced by the instrument.
NMR uses RF pulses to transfer energy to NMR-active nuclei, causing them to precess and
generate a signal. This signal then undergoes a free induction decay (Fig. 12), and the rate of this
decay determines the rate the instrument can apply the RF pulses. Nuclei in different chemical
environments will precess at different rotational frequencies, and these rotational frequencies
correspond to different chemical shifts in a full NMR spectra. In MRI, the resonance frequency in
the presence of a magnetic field gradient determines the signal location, while the intensity of the
MRI signal is dependent on the rate at which the nuclei signals decay and/or grow back. 26–31
To run a scan, the computer is programmed with the appropriate pulse sequences and
experimental parameters then sends this information to the instrument so it may begin the
acquisition. The information in the signal that is produced from the sample or patient is extracted
9

with a demodulator and sent through an analog-digital converter so that the computer can
understand the data. The computer then applies a Fourier transform along with other data
processing techniques to obtain the final MR image. 32

Figure 11: Diagram of a typical MRI instrument (a) and magnetic coils housed inside (b) which generate and
detect the magnetic fields during each scan. Image credit: National MagLab.33,34 Used with permission.

MRI instruments generate a constant, non-fluctuating magnetic field (referred to as B0) and
apply repeating RF pulse sequences using various magnetic coils (Fig. 11b) to manipulate nuclei
with magnetic spins (such as 1H, 2H, 13C, and 14N). The direction of the homogenous B0 field is the
designated z-axis that the nuclei align themselves with in a parallel fashion. In a typical RF pulse
sequence, once the nuclei are aligned within the B0 field, they are rotated 90° degrees into the xyplane with a RF pulse. Any protons that have components that are not aligned with the z-axis
generate a signal that can be detected by the RF receiver. Immediately after, they begin to precess
along the z-axis as they start to realign with B0. Eventually, the nuclei will return to equilibrium
where their signal reaches zero. This is the free induction decay of the signal. (Fig. 12)

Figure 12: (Above) Typical free induction decay which, after a Fourier transform is applied, gives a signal at
a specific frequency. (From Wikipedia and used as-is under a CC BY-SA 3.0 license.)
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T1 and T2 Relaxation
T1 and T2 are characteristics that describe the ways in which 1H signal decays after being
tipped into the xy-plane. Both occur in tandem; There cannot be one without the other. The
relaxation time constant T1 describes how long it takes the longitudinal signal to recover ~63% of
its initial value and occurs due to the net magnetization of the 1H spins realigning with B0. (Fig. 13)
The time constant T2 describes how long it takes the signal to irreversibly decay to 37% of its initial
value and occurs due to 1H spins spreading out in all directions (i.e., dephasing) across the xy-plane
(Fig. 14).

Figure 13: (Above) T1 relaxation diagram showing net magnetization vector returning to equilibrium with B 0
field following a RF pulse. In T1 relaxation, signal decay is due to protons realigning with B0.

Figure 14: (Above) T2 relaxation diagram showing dephasing of spins in the xy-plane following a RF pulse.
In T2 relaxation, signal decay is due to proton spins dephasing and spreading out in all directions across the
xy-plane.

The clinical CAs currently available today are considered low relaxivity and tend to have r1
values of ~4 mM-1s-1 (Fig. 15) whereas high relaxivity CAs are reported to have r1 values upwards of
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and 8-10 mM-1s-1. This increase in r1 value between low and high relaxivity CAs means each
individual CA molecule is that much more effective in enhancing MRI contrast. 27
25
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Figure 15: (Above) T1 relaxivities of some commercial MRI CAs compared to free Gd 3+ (gray). Data initially
published by Dr. Joseph Hornak at RIT.

The relaxation of protons occurs due to energy transfer from the magnetic dipole of a
paramagnetic ion (Gd3+, in this case) to the protons themselves.13 Molecular parameters such as
hydration, water exchange kinetics, and correlation time of a particular chelation complex are the
three main factors that affect the extent to which this energy is transferred. 13 Water can exist in any
of the three coordination spheres of the complex (the inner coordination sphere, the second
coordination sphere, and the outer coordination sphere). Hydration number refers to the number
of water molecules that can coordinate to the metal ion. The relaxivities of the water protons in all
three spheres come together and contribute towards the overall r1 of the complex. However, only
water in the inner-most sphere is able to coordinate directly with the metal.35,36 (Fig. 16) Another
parameter than affects r1 is rotational entropy. Rapid rotational motion and tumbling in solution
produce additional magnetic fluctuations which results in a decreased relaxivity rate.13 These factors
influence the time it takes water protons to realign themselves within the B 0 field, and therefore
how long a 1H signal will last in one area of the body versus other areas. Hence the term “contrast”,
these differences are visualized as dark and light regions in the final MR image and correspond to
slower and faster r1 values, respectively.
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Figure 16: (Above) Diagram of water molecules in the outer and inner coordination spheres of a CA. 37
(Used with permission from Werner et al.)

Contrast Agents and Their Limitations
Contrast agents coordinate to water molecules and cause their protons to respond to
magnetic field fluctuations at much faster rates than the protons of water molecules which do not
coordinate with them. In other words, they shorten the relaxation time constant (T1) of water
protons, and better CAs shorten T1 to a greater extent per molecule of agent. Relaxation time
constants are the inverse of relaxation rate constants, so the inverse of T1 is the relaxation rate
constant R1. (Fig. 17) However, the T1 and R1 of a given CA vary with how much of the agent is
present and therefore must be related to concentration. This function is the relaxivity, or r1, of the
CA, and it describes how the relaxation rate constant, R1, changes as a function of its
concentration. Thus, r1 is expressed in units of inverse millimolar seconds (mM-1s-1).13,37 (Fig. 18)

1
R1 =
T1
Figure 17: (Above) Equation for relaxation rate constant.

r1 =

1
∆ (T )
1

∆[M]

Figure 18: (Above) Equation describing T1 relaxivity (r1). CAs cause T1 to decrease which increases the 1/T1
value, thus increasing r1.
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Most of today’s clinically used CAs are small molecules (MW of approx. less than ~500600 g/mol) containing the heavy metal Gd3+ held by a chelation complex. Gadolinium is used
because its paramagnetic properties are what make it effective at increasing the MR signal. The
seven unpaired electrons of Gd3+ give it a high magnetic moment, making it an ideal candidate to
be used as a CA.37 Chelators used in MRI contrast agents for Gd can be classified into two main
types of structures: Linear and Macrocyclic. As their names suggest, linear chelators by themselves
are open chains that wrap themselves around a metal ion whereas macrocyclic chelators already
have a set ring structure that is made to fit one metal ion inside them.
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (Fig. 19, left) is a
macrocyclic chelator that has been used extensively in our group for chelation of Gd. DOTA has
four acetic acid groups that each offer one point of attachment for the Gd metal. These four acetic
acid groups, along with the lone pairs on the four nitrogen atoms of the ring, fill all eight of Gd’s
chelation sites and hold it very tightly within an octadentate coordination. For the dissociation
reaction ML → M + L where M is the metal, L is the ligand, and ML is the metal with bound
ligand, DOTA was found to have a very high thermodynamic stability of logK of ~25.3.38,39 It is
important that Gd does not fall out of its chelation because free-floating Gd3+ metal in the body is
toxic to the kidneys. Similar to DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(tert-butyl acetate)
(DO3A) (Fig. 19, middle) is also a macrocyclic chelator except it does not have a fourth acetic acid
arm like DOTA. Even so, the short alanine side chain that our target compound is based upon
positions the chelation complex close enough to the amino acid backbone that the coordinated
Gd3+ can reach the C-terminus and use it as its eighth chelation site.38 (Fig. 19, right)

Figure 19: (Above) Structures of macrocyclic chelators DOTA (left), DO3A (middle), and Gd-DO3A
(Dotarem). (right)
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The r1 relaxivities of current CAs fall around the range of 4-5 mM-1s-1 and are typically
administered at a standard dose of 0.1 mM/kg (approximately 0.2 mL/kg) at 10 mL per 15 seconds
to enhance contrast.40 Despite the progress in cancer diagnosis and treatment that these
organometallic structures can be attributed to, there are a few main issues with today’s CAs that
cannot be overlooked. Many of today's CAs lack cell-specific targeting, enabling them to freely
travel throughout the entire circulatory system. 27,35 At best, some can only target a single organ
system or ubiquitous cellular structure, but this is often still not good enough to achieve earlier
cancer detection. This limitation increases the concentration that is required to be present in the
body for the MR instrument to produce a usable image. The duration of an MRI lasts anywhere
from 15 to 45 minutes (although some can take an hour or more).35,37,40 For patients that need
multiple MRI scans to monitor their malignancy, this can add up to a significant amount of CA that
is administered intravenously. Lastly, the high toxicity of unbound Gd3+ is due to its ionic radius
which is similar to that of calcium, giving it a high affinity for Ca 2+ ion channels.37 Since Ca2+ is
crucial for nerve transmission, muscle contractions, blood coagulation, and the function of
mitochondria, free Gd3+ can disrupt these biological systems and negatively impact health.
Overall, linear chelators have lower chelating stability than their closed-chain counterparts,
making it more likely for Gd3+ to dissociate from the complex and freely circulate the body. Linear
chelators are associated with nephrogenic system fibrosis, a potentially life-threatening disease that
is caused by free Gd3+ ions and results in progressive tissue fibrosis across the entire body. 38
Examples of these open chain complexes are Magnevist, Omniscan and OptiMARK, as shown in
the top and bottom rows of Figure 20 below. In one study, in patients with normal renal function,
only those who received linear-type Gd CAs were found to have Gd3+ deposition in certain brain
regions. While there were no observable symptoms in response to Gd 3+ deposition in the brain in
this particular study, it is in the best interest of patient safety that any unintended Gd 3+ deposition
be prevented as much as possible.39 Furthermore, a 2019 study described the toxic effects that Gd 3+
CAs can have on mitochondrial function and cell viability in basal ganglia cells. 41 Therefore, the
design of new CAs must take into consideration patient safety and minimize the risk of Gd falling
out of its chelation as much as possible.38
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Figure 20: (Above) A selection of commonly used commercial aminocarboxylate-based MRI CAs.37 Used
with permission from Werner et al.

So far, CAs from our work have possessed r1 values similar to those of commercial agents.
However, we previously achieved high relaxivity by attaching two low-relaxivity complexes to the
same molecule. The red line on the graph in Figure 21 below shows our previously synthesized DiLys(Gd-DOTA) which we found had an r1 of 11.33 mM-1s-1. While effective, the use of two Gd
atoms per CA does not help reduce the amount of metal ion entering a patient's body. Therefore,

r1

designing single chelate CAs that are more effective at increasing r1 is a superior approach.

Figure 21: (Above) T1 relaxivities (r1) of CAs from our previous work compared to Dotarem (green).
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Synthetic Approach
Modular Approach to TMIA Synthesis
Our group synthesizes modular compounds for molecular imaging. The synthetic design
splits these modules into two groups based on their functionality: imaging modules and targeting
modules.42 Due to the modular nature of these structures, all of them can be linked to one another
through simple coupling reactions to construct a targeted molecular imaging agent (TMIA) for a
particular imaging modality to target a specific biomarker. (Scheme. 1) For these applications,
amino acids are favorable due to their bioavailability and biostability. 43 Additionally, since the
reagents, methods, and coupling mechanisms for peptides are well known, we can focus on
developing new TCAs instead of new reactions. In our earlier work, the lysine side chain was
chosen to attach the DOTA chelating group for imaging. 42 However, for our current purposes,
alanine is chosen instead because its shorter chain length allows Gd to chelate to the amino acid
backbone, lowering the rotational entropy of the complex and contributing towards higher T1
relaxivity.13,27,35–37 This new chelation complex design would require the development of a new
synthetic route to modules (i.e. “puzzle pieces”) containing the rotationally restricted alanine
analogs.

For PET:
M = La or Ce
later
exchanged to
Cu, Ga, or In

For MRI:
M = Gd

Targeting Urea
DCL

Contrast Agent
M-DOTA

DCL-DSS
Coupling

Contrast Agent
Linker DSS

DCL-DSS-Lys(M-DOTA)-NH2
DCL-DSS

Scheme 1: General synthetic approach for TMIAs using DCL pre-coupled to DSS linker. The metal
(shown as M) can easily be customized depending on the desired imaging modality.
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Synthetic Approach to High Relaxivity Contrast Agents
Previously, contrast agents in our group have been built using a lysine derivative that is Nterminally protected by Fmoc because it is inexpensive and can be incorporated easily into solid
phase peptide synthesis (SPPS). Additionally, its primary amine side chain is easily coupled to
chelating groups (such as DOTA) which hold metal ions, allowing the molecule to be used with
various imaging methods depending on the metal that is chosen. 42,44–46 While lysine works as a
starting place upon which to construct a CA, it is not a suitable scaffold from which to build one of
high-relaxivity because of the long 4-carbon chain (Fig. 23, pink) between the chelation complex
and amino acid backbone. This distance makes it difficult to control the rotational entropy, one of
the molecular parameters that affects a contrast agent’s ability to increase r1.35,36

Figure 23: (Above) Structures of CA modules based on Lysine (left) and Alanine (right).

Novel Use of Metals as DO3A Protecting Groups
In this approach, the three free acid groups of DO3A can be protected from unwanted
reactivity by chelating Gd3+ early in the synthesis. This early chelation allows the metal to prevent
the carboxylic acid arms from participating in unwanted side-reactions. Other synthetic approaches
leave these arms protected by tert-butyl groups and cleave them in the final steps with TFA just
before the metal chelation step. The downside of this approach is that this exposes the entire
TMIA to the harsh conditions of TFA, thus risking its decomposition. The removal of t-butyl
groups on DOTA was found to require exceedingly harsh acid (100% TFA) compared to isolated
esters (such as on the side chain of glutamic acid) which only requires just 10% TFA. Such harsh
treatment has resulted in degradation of precious peptides in our lab. The early metal chelation
18

avoids harsh deprotection conditions on the final TMIA and reduces the risk of degrading the
overall TMIA. This method of chelating the metal early has been utilized by our group extensively
with DOTA and is shown to be just as reliable with DO3A.

Evaluation and Analysis of Compounds
Compounds

were

assayed and

characterized with

liquid chromatography-mass

spectrometry (LC-MS), and high-resolution mass spectroscopy (HRMS). T1 relaxivity experiments
of compounds were run on a 43 MHz Magritek NMR spectrometer. Details of these methods can
be found in the experimental section.

Results and Discussion
Schemes 2a and 2b outline the synthetic design we envisioned and embarked upon.
Scheme 2a is a modification of the approach by Boros et al.35 which seeks to introduce the Gd
early in the synthesis (step vi) and remove the t-butyl groups early (step iv) rather than after the
module is coupled to a peptide. Our modular approach only utilizes the t-butyl groups in the
assembly of the precursor to the Ala(DO3A) macrocyclic chelator. By immediately removing these
groups and chelating Gd early in the synthesis (step viii), we eliminate any chance of exposing the
final HR-TCA to the brutal t-butyl deprotection conditions known to be destructive to peptides.
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Scheme 2a: (Above) Part 1 of the reaction schematic for the proposed HR-TCA.

The synthesis began with Cbz-Ser(H)-OBn (1), a commercially available Serine derivative
that is protected at the N-terminus by a carboxy benzyl group and protected at the C-terminus by a
benzyl group. The side chain was then reacted with methane sulfonyl chloride (1.2 eq) in DCM
under basic conditions (1.6 eq TEA) to afford the crude Cbz-Ser(Ms)-OBn (2) which was easily
purified by liquid-liquid extraction and obtained at >98% yield. (Scheme 2a, step i)
Mesylate groups are excellent leaving groups and easily displaced by primary and
secondary amines such as those in cyclen, an aza-crown ether. Displacement of the mesylate group
by cyclen formed the foundation for the macrocyclic chelation complex, Cbz-Ala(Cyclen)-OBn (3).
(Scheme 2a, step ii) This was run by dissolving excess cyclen (4 eq) into ACN with1.5 eq of
inorganic base K2CO3 and heating the mixture to 65°C. Once heated, compound 2 was dissolved in
ACN, added dropwise, and allowed to react for 16 hours. When completed, compound 3 was
purified with liquid-liquid extraction and obtained in approximately 82% yield.
The remaining three secondary amine groups of the cyclen ring were alkylated by
dissolving Cbz-Ala(Cyclen)-OBn (3) in acetone with K2CO3 (1.5 eq) and tert-butyl bromoacetate
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(3.2 eq). (Scheme 2a, step iii) The mixture was allowed to react for 16 hours at room temperature
and then was purified with liquid-liquid extraction to afford Cbz-Ala(DO3A-tBu3)-OBn (4) at 90%
yield.
Tert-butyl groups were removed by dissolving 4 into pure TFA and adding 2 eq of TIPS as
a hydride donor to counteract formation of the tert-butyl radical cation. (Scheme 2a, step iv) The
reaction was allowed to react for a maximum of 5 hours. Its progression was monitored by taking
hourly aliquots of the mixture, removing the TFA in vacuo, and assaying in LC-MS. The reaction
was deemed finished when the product peak 658.14 m/z appeared as the base peak while mass
peaks 714 m/z and 770 m/z of intermediates Cbz-Ala(DO3A-tBu1)-OBn (4b) and Cbz-Ala(DO3AtBu2)-OBn (4c) (Fig. 24), respectively, were no more than 15-20% of the total ion intensity. To stop
the reaction, the entire reaction flask was attached to a rotary evaporator to remove the bulk of the
TFA. When the initial reaction volume was reduced as much as possible, ~10-20 mL of ACN was
added and the mixture was concentrated in vacuo again to continue pulling off any remaining
TFA. This rotary evaporation was performed 3-4 times to pull off as much TFA as possible prior
to purification on a Biotage Selekt with flash HPLC and Biotage Sfär C18 30g column. (Scheme
2a, step v) All fractions were assayed via direct injection mass spectrometry. Pure fractions were
collected and concentrated in vacuo before being freeze dried to obtain incredibly pure CbzAla(DO3A)-OBn (5) in 24.74% yield.

Figure 24: (Above) Diagram of tert-butyl deprotection showing the formation of desired product (5), and
mono- and di-tert-butyl intermediates 4b and 4c, respectively.
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To chelate Gd, freeze dried compound 5 was combined with 3 eq of Gd(OAc)3 in 5mL of
15% ACN in 5mM AmAc buffer (Scheme 2a, step vii). The mixture was then purified via flash
chromatography on C18 silica using a gradient of 10%-50% ACN in 5mM AmAc buffer increasing
in concentrations of 10%. Pure fractions were concentrated in vacuo and freeze dried to afford
compound 6 in 73.4% yield. Compound 6 represents the departure from the literature approach
by Boros et al (ref) as the Gd module replaces the t-butyl protected chelator, DO3A, in the
remainder of the synthesis. As described earlier, the protection of the DO3A by the Gd metal
itself avoids the harsh deprotection steps required at a later time point in the synthesis where the
valuable peptide has been assembled.
Removal of the carboxybenzyl and benzyl protecting groups of Cbz-Ala(Gd-DO3A)-OBn
(6) was first attempted via catalytic hydrogenation with formic acid, 20% Pd/C, and H 2 gas, but the
success rate of this method proved too slow to be practical and often left the carboxybenzyl group
untouched. We resorted to removing the carboxybenzyl and benzyl protecting groups with
palladium black and vigorous H2 gas in methanol. Compound 6 was combined with 1 eq Pd Black
in MeOH and allowed to react for 1 hour while H 2 gas was rigorously bubbled into the reaction.
Upon completion, the reaction mixture was filtered then concentrated in vacuo. Not all catalyst
was able to be removed from the crude reaction and most likely contributed to excess yield. The
remaining residue was freeze dried to afford H-Ala(Gd-DO3A)-OH (7) in > 100% yield. (Scheme
2a, step viii)

Use of Tryptophan as a Spacer
After initial synthetic attempts to couple the H-Ala(Gd-DO3A)-OH (7) directly to the
linker and targeting group, we decided to couple an Fmoc-protected tryptophan to H-Ala(GdDO3A)-OH (7) to add hydrophobicity in an attempt to assist with separation of the final HR-TCA
(10) on C18 silica. The addition of the tryptophan also increases lipophilicity, enhancing
bioavailability and cell permeability. Additionally, tryptophan’s absorption of 270nm wavelength
light would assist in visualizing the product on HPLC. Furthermore, we suspect that the increase in
molecular weight would decrease the overall molecular tumbling rate in solution and provide
another means by which the relaxivity is enhanced.
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To synthesize compound 8, 1 eq of Fmoc-Trp-OH was first combined with 20 eq of
DIPEA, 1.2 eq of coupling agent TSTU, and ~10 mL of DMF in a reaction flask in order to
activate the carboxylic acid for coupling. Prior to addition of compound 7 to this mixture, FmocTrp-OH was first confirmed to be properly activated. This was done by removing a 20-minute
aliquot of the mixture, crashing it out of solution with diethyl ether, spinning down the precipitate,
and removing the decant. To the precipitate, one drop of 0.1% aqueous octylamine was added and
one drop of this was placed into an HPLC vial and filled the rest of the way with diH 2O. The
prepped aliquot was assayed with both direct injection mass spectrometry and LC-MS. When only
Fmoc-Trp-Octylamine molecular weight in positive ion (538 m/z) mass spec is observed with no
Fmoc-Trp-OH starting material, the activation mixture was deemed ready to be combined with HAla(Gd-DO3A)-OH (7). To a separate flask or vial, compound 7 was first dissolved into 5-10 mL
of DMF with 20 eq of DIPEA and then added to the activated Fmoc-Trp-OH mixture and
allowed to stir for about 1 hour. When finished, the reaction mixture was concentrated in vacuo to
remove ~50% of the DMF. The product was crashed out of solution with diethyl ether, vortexed,
and centrifuged. The supernatant was discarded and the precipitate, crude Fmoc-Trp-Ala(GdDO3A)-OH (8), was dried under Ar(g) and then run through reverse phase C18 SPE with 10%-60%
ACN in 5mM AmAc increasing in 5% increments. (Scheme 2a, step ix) The pure fractions were
combined, concentrated in vacuo, and freeze dried to obtain pure Fmoc-Trp-Ala(Gd-DO3A)-OH
(8) in 36.96% yield. (Scheme 2a, step x)
Compound 8 was dissolved into DMF with 24 eq of diethylamine (DEA) base.
Immediately after combining, the pH was confirmed to be sufficiently basic (pH of at least 10).
The reaction was run for 2 hours, at which time the compound was crashed out of solution with
diethyl ether, vortexed, and spun down. The supernatant was discarded, and the precipitate was
dried under Ar(g). The precipitate was dissolved into diH2O with 1 μL of TEA and then freeze
dried overnight to afford H-Trp-Ala(Gd-DO3A)-OH (9) at 75-77.78% yield. (Scheme 2b, step xi)
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Scheme 2b: (Above) Part 2 of the reaction schematic for the proposed HR-TCA.

Step xii in Scheme 2b above outlines the convergent point of our synthetic approach: The
convergent coupling of the premade DCL targeting group (red) with the DSS linker (purple) to
compound 9. This was done by dissolving compound 9 into DMF with 10 eq of TEA under Ar(g).
Once dissolved, 1 eq of the premade DCL-DSS was added and allowed to react for 2-3 hours.
When finished, the product (now crude compound 10) was crashed out of solution with diethyl
ether, vortexed, and centrifuged before drying over high vacuum overnight. The dried crude
compound 10 was run through a manual C18 flash chromatography with 2-30% MeOH in 5mM
AmAc, increasing in 2% increments. Pure fractions were combined, concentrated in vacuo, and
freeze dried. The compound was redissolved again in a small volume of diH2O and filtered
through a 0.3 μm syringe filter and then freeze dried a second time. Once more, the compound
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was redissolved in diH2O, filtered through a fresh 0.3 μm syringe filter, and then freeze dried for
the third and final time to obtain the final HR-TCA, DCL-DSS-Trp-Ala(Gd-DO3A)-OH (10), at
60.4% yield.

The Struggle of Optimizing the tert-Butyl Deprotection with TFA
The true struggle of this synthesis was the removal of the tert-butyl protecting groups. The
literature method outlines using a mixture of DCM and TFA heated to 55°C. (Table 1, Trials 1-2c)
This method was found to generate nothing but impurities with no semblance of product. In fact,
we discovered that addition of DCM to the reaction slowed progress so much that it became
impractical to even consider using a TFA concentration of anything less than 90%.
Removal of the tert-butyl group results in generation of unstable tertiary carbocations.
Radical scavengers were investigated as a means of avoiding accumulation of the tert-butyl radical.
Various trials of pure TFA solvent with varying amounts of anisole were run, but this was also
unsuccessful and showed no improvement. (Table 1, Trials 2a-2c) Over the course of just 30-60
minutes, the mixture also showed evidence of oxidation due to its appearance changing to a dark
brown similar to that of black earl grey tea. Thus, it was concluded that a more generous flow of
argon gas should be used to prevent oxygen reactivity at the surface of the solution as much as
possible. Next, we tried plain TFA by itself at room temperature and ensured a vigorous flow of
Ar(g) gas was maintained over the reaction for its entire duration. This resulted in greater than 100%
yield and many impurities. No product peak or any other recognizable peaks could be identified
when analyzed by LC-MS. In a desperate attempt to see any semblance of product formation, the
reaction was placed into the freezer overnight which unsurprisingly was not helpful. However, the
lack of any significant oxidation (i.e., the reaction solution remained exceptionally clear and
transparent, similar to that of raw egg whites) could have been attributed to the higher argon gas
flow. (Table 1, Trial 3)
Yet another series of tert-butyl deprotection trials were performed to see if Gd could be
chelated alongside the deprotection step using various ratios of DCM, Gd(OAc)3, and TFA. (Table
1, Trials 4a-4c) While one of the trials was shown to contain the chelated compound 6, yield was
abysmal, and LC-MS showed a base peak of an impurity with 716 m/z in positive ion mode.
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(Scheme 3) Therefore, it was concluded that it is not possible to chelate Gd into the crude
reaction.
Diving into literature revealed mixtures of TFA, dithiothreitol (DTT), TIPS, and H2O to
create a “Cleavage Cocktail” that is typically used in solid phase peptide synthesis and is formulated
specifically for a particular peptide and its protecting groups. They are used to simultaneously
remove protecting groups and cleave the peptide from its resin. The first attempt of using this
Cleavage Cocktail was unsuccessful, but the second attempt (Table 1, Trial 5) showed promise in
formation of mono- and di-tert-butyl intermediates (previously shown in Figure 24). After many
reformulations of the Cleavage Cocktail (Trials 5-12, Trials 10-11 not shown), progress finally
showed with a taller product peak and decreased peaks of side reaction byproducts and impurities.
(Table 1, Trials 6-9) Attempts were made to use other protecting groups such as ethyl and benzyl
by instead reacting the free amines of Cbz-Ala(Cyclen)-OBn (3) with ethyl and benzyl
bromoacetate, respectfully. All attempts to remove these protecting groups were unsuccessful.
Therefore, the decision was made to stick with the tert-butyl protecting group approach.

Scheme 3: (Above) Potential unwanted side reaction caused by TFA and TIPS possibly forming a reducing
agent and transforming one of the t-butyl esters into either an acetal (4b) or hemiacetal (4c) in extreme
acidic conditions.47

Many more tert-butyl deprotection trials resulted in the reaction time being limited to 5
hours since anything more was found to result in a messy spectra and significantly lower yields.
Eventually, it was discovered that use of DTT in the Cleavage Cocktail could potentially have
negative downstream effects on the synthesis. Any residual DTT remaining with compound 5
following tert-butyl deprotection could possibly poison the metal catalyst during the Pd catalyzed
hydrogenation of step viii in Scheme 2b. This was hypothesized because it was near impossible to
remove the Cbz and Bn protecting groups from one specific batch of compound 6 whose lineage
could be traced back to a batch of Cbz-Ala(DO3A)-OBn (5) that was obtained by using the DTTcontaining Cleavage Cocktail. In comparison, all batches of Cbz-Ala(DO3A)-OBn (6) whose
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precursor compound 5 was obtained using deprotection conditions of only TIPS+TFA always
progressed. It was decided at this point to forego use of the Cleavage Cocktail in favor of only 2 eq
of TIPS to counteract formation of the radical cation and prevent any downstream consequences
of the sulfur-containing compound potentially hindering the Pd catalyzed hydrogenation. (Table 1,
Trial 15)
Ultimately, the tert-butyl deprotection required the use of pure TFA as the solvent, along
with 2 eq of TIPS as a hydride donor and radical scavenger. While this deprotection step was the
most grueling and time-consuming step of the synthesis to work out, the optimized procedures
were able to afford Cbz-Ala(DO3A)-OBn (5) in yields ranging from 12.9%-24.74% at near 100%
purity (Table 1, Trials 16-20), a huge improvement over the previous < 5% yield at abysmal purity.
To overcome the low yield amount, we employed a “go big so we don’t have to go back” approach
which involved running the tert-butyl deprotection at scales upwards of 3.0-4.0 g to ensure
adequate yields of 150-300 mg could be obtained to move forward in the synthesis. (Table 1, Trials
18-20) Overall, it took more than 20 runs of the tert-butyl deprotection, at least 18 manual C18
SPE purifications, and months of grueling HPLC method development to achieve these
improvements in yield and purity.

Trial

Identifier

1

Attempt 1: From Literature

2

Anisole Trials

2a

Scale

Crude %
Yield 5

Pure %
Yield 5

Purity

532 mg

14%

N/A

Abysmal

Flask 1

54.6 mg

N/A

N/A

N/A

2b

Flask 2

52.0 mg

N/A

N/A

N/A

2c

Flask 3

51.4 mg

91%

N/A

Abysmal

3

Ice Bath/Freezer

217 mg

> 100%

N/A

Depressing

27

Important Takeaways for Future
Investigators
Must use Ar gas.
Something must be done about
accumulation of tBu carbocation.
DCM may slow rxn rate
Barely any product formation.
Anisole is bad.
Need faster Ar flow.
Abysmal purity.
Semblance of product formation. Better
Ar flow = less oxidation as rxn progresses.

4

Simultaneous Gd Chelation Trials

4a

Flask 1

50 mg

N/A

N/A

4b

Flask 2

50 mg

N/A

N/A

4c

Flask 3

50 mg

N/A

N/A

N/A

N/A

DCM slows rxn down too much. Do not
use DCM.

N/A

Should give Cleavage Cocktail one more
chance since we determined the reaction
was removed too soon. Already saw good
progress in the form of mono- and di- tBu
intermediates.

5

2 Cleavage Cocktail

6

"Noche" 2 Cleavage Cocktail
and Excessive TIPS Out of
Desperation

7

"Dos Noches" 3 Cleavage
Cocktail

300 mg

16.50%

8

4 Cleavage Cocktail

300 mg

9

1 Modified Cleavage Cocktail
(Double Mol% of TIPS)

300 mg

12

4 Modified Cleavage Cocktail w/ DCM Trials

12a

Flask 1: 50 mg sm + 5 mL
Cleavage Cocktail

50 mg

N/A

N/A

N/A

Impurities everywhere. Maybe we just
need better purification.

12b

Flask 2: 50 mg sm + 5 mL 75%
Cleavage Cocktail in DCM

50 mg

N/A

N/A

N/A

Never again DCM. Rxn too slow.
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Cleavage Cocktail: HPLC/SPE Method Development - 500 mg Scale

13a

"Hail Mary" Biotage

N/A

New approach: Optimize purification and
go big so we don't have to go back.

nd

50 mg

Never chelate and deprotecting tBu at the
same time.

~20%

Cleavage Cocktail/radical scavengers
proving promising. Ran overnight in
freezer to try and slow reactivity of tBu
radical cation.

N/A

~20%

Mass spectra are looking better. Focus is
now directed at improving C18 SPE. Cold
temp of freezer is hypothesized to help
prevent unwanted reactivity.

N/A

N/A

N/A

Potentially need to add more Cleavage
Cocktail reagents (DDT and TIPS) to
better counter radical formation.

> 100%

N/A

N/A

Speculations about why > 100% yield.
Unsure if extra TIPS did anything helpful.

nd

167 mg

12.50%

N/A

rd

th

st

The small amt of DCM used to try to slow
rxn and decrease bi-product formation did
nothing.

th

23.7 mg
of crude

0%

N/A

50:50 mixed solvent system of
MeOH:ACN 10%-70% in diH O did not
improve peak separation.
MeOH 30-70% seems to work best
separating 812 from 716 m/z pos ion.
2

13b HPLC Method Development 1

13c

SPE Method Development 1:
Based on HPLC Method
Development 1

30 mg of
crude

0%

N/A

N/A

Used gradient HPLC Method
Development 1.
No product recovered. Should try
different solvent system.

13d HPLC Method Development 2

50:50 mixed solvent system of MeOH and
ACN 30-70% in diH O showed improved
peak separation.

SPE Method Development 2:
13e Based on HPLC Method
Development 2

2

40 mg of
crude

0%

N/A

N/A

30%-70% MeOH in diH O, increasing by
5%. Chelated 1.5 eq Gd.
Need to figure out why Gd falls out of
chelation. Possible suspects: MeOH,
unbuffered solvents, the C18 silica itself.
Decide to try buffered SPE solutions.

11.1 mg
of crude

0%

N/A

N/A

SPE with 10%-40% ACN in 5mM AmAc.
For each conc, collected 3 fracs in
50x100mm test tubes, approx. 12.5mL

2

13f

SPE Method Development 3:
Based on Failures from Method
Development 2
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Gd(OAc) vs GdCl
3

13g

per tube. Fracs sat out in 5mM buffer. Bn
first observed to be lost. Gd stayed in.
Too much compound lost during SPE to
be recovered.

3

SPE Method Development 4:
New bottle of Gd(OAc) . Test to 10 mg of
see whether terminal Bn group
crude
is lost in unbuffered solution.
3

N/A

Chelated 2 eq of new Gd. SPE run 10%40% ACN in diH O, increasing by 10%. 3
50x100mm test tubes per conc, approx.
12.5mL per test tube.
Bn is not cleaved in absence of buffer.
Too small amt product to be recovered.

N/A

C18 likely not responsible for loss of Gd.
Finally discovered 716m/z is not mono
tBu, but instead acetal or hemiacetal, aka
PUBLIC ENEMY #1.
We need use buffer.
Identified EVIL MASSES (in pos ion):
716 = 1 tBu, 1 Acetal
772 = 2 tBu, 1 Acetal
774 = 2 tBu, 2 Acetal

2

0%

N/A

13h Another Biotage

115 mg
of crude

12%

N/A

14

One Final Cleavage Cocktail

547 mg

17.00%

N/A

14a

SPE of Chelated 14

93 mg of
crude

11.12%

N/A

15

No more Cleavage Cocktail

No more DDT.

15a

Biotage of entire Crude
Cbz-Ala(DO3A)-OBn

Possible correlation between amt of TIPS
and amt of Public Enemy #1 (716 m/z pos
ion) generated during rxn. Less TIPS
might = Less 716.
Maybe Biotage isn't to be trusted

16

Less TIPS (2 eq)

16a

Biotage of Unchelated 15

17

Go Big So We Don't Have To
Go Back

17a

Biotage of Unchelated 16

18

Go REALLY Big So We Don't
Have To Go Back

18a

Biotage of Unchelated 17

19

Go REALLY Big (Again) So
We Don't Have To Go Back

19a

Biotage of Unchelated 18

20

Go REALLY Big (Yet Again) So
We Don't Have To Go Back

20a

Biotage of Unchelated 19

Suspicious Only somewhat improved yield
N/A

Maybe too much product loss. Perhaps
due to silica?

282 mg

N/A

N/A

244 mg

N/A

13.45%

> 90%

Progress! Very low yield but
improvements in purity make up for it!

584 mg

N/A

10.58%

~90%

Biotage is, in fact, trustworthy

3200 mg

N/A

12.39%

> 95%

Most optimized procedures to date

3700 mg

N/A

7.56%

> 95%

2387 mg

N/A

14.50%

> 90%

Table 1: (Above) List of selected tert-Butyl deprotection experiments in chronological order, summarized.
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To use buffered solution, or not to use buffered solution? That is The Question!
Chelating crude Cbz-Ala(DO3A)-OBn (5) with Gd(OAc)3 was shown to never be
successful, so a purification with a reverse phase C18 silica is required beforehand. Following
collection and rotary evaporation of pure fractions, the purified Cbz-Ala(DO3A)-OBn (5) was
redissolved in ACN with AmAc buffer and chelated with Gd(OAc)3. The resulting crude CbzAla(Gd-DO3A)-OBn (6) was put through a quick reverse phase SPE to get rid of excess Gd. Once
Gd is chelated, the compound should never be allowed to sit in unbuffered solution, nor should it
ever touch acidic buffer, otherwise Gd falls out of chelation, reverting it back into Cbz-Ala(DO3A)OBn (5). This unintended demetallation is undesired because it requires re-chelation of Gd and
yet another SPE on C18 silica, resulting in unnecessary loss of product and time. Alternatively,
when Cbz-Ala(Gd-DO3A)-OBn (6) is allowed to sit in AmAc buffer for any longer than 2 hours at
room temperature, it results in loss of the benzyl group. We suspect this is due to the Gd
facilitating hydrolytic cleavage through its coordination bond to the ester of the benzyl protecting
group (Scheme 4).

Scheme 4: (Above) Schematic of basic buffer-dependent side transformation of compound 6.
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The End Game: Convergent Coupling of Imaging Module to Targeting Module
The coupling of Fmoc-Trp-OH with H-Ala(Gd-DO3A)-OH (7) was easily carried out with
peptide coupling agent TSTU and purified on C18 silica to afford Fmoc-Trp-Ala(Gd-DO3A)-OH
(8). A simple Fmoc deprotection with DEA yielded the HR CA module, H-Trp-Ala(Gd-DO3A)OH (7), which was then conveniently coupled to in-house synthesized targeting group and linker,
DCL-DSS, to successfully obtain the final HR-TCA, DCL-DSS-Trp-Ala(Gd-DO3A)-OH (10).
This step completed the designed convergent coupling of the imaging module, H-Trp-Ala(GdDO3A)-OH (9), to the targeting module, DCL-DSS.

Relaxivity Measurements
The T1 efficiency of an MRI contrast agent is its spin-lattice relaxivity r1 in mM-1s-1. T1
relaxivity (r1) of CA solutions between 0 mM and 5 mM was measured with an inversion recovery
pulse sequence, plotted vs. concentration, and relaxivities were measured as the slope.
The details of each set of measurements are in the experimental section below. As
observed in the graph in Figure 25 below, all the agents exhibited a T1 relaxivity modestly higher
than Gd-DOTA (Dotarem) (red) which has a relaxivity of 4.1 mM-1s-1. While the modest increase
in relaxivity is disappointing, it is speculated that higher relaxivity in the constrained Ala(DO3A)
system (as described in the Boros paper35) is only realized after a certain critical mass in a longer
peptide or by other effects of larger substituents on close-by neighboring side chains.
This speculation is further substantiated by the surprising results exhibited by the FmocdTrp-Ala(Gd-DO3A)-OH (8) with substantially higher relaxivity than the other compounds (Fig.
25) at the higher concentrations (of 2, 3, 4 and 5 mM). However, the curve itself is not completely
linear and appears to be bi-phasic, with similar relaxivity values as the rest of the compounds in the
series at lower concentrations (0.5, 1 and 2 mM).
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T1 Relaxivity vs Concentration
Gd-DOTA

DCL-DSS-Trp-Ala(Gd-DO3A)-OH

Fmoc-dTrp-Ala(Gd-DO3A)-OH

H-dTrp-Ala(Gd-DO3A)-OH

120
100

1/T1 (s-1)

80

60

y = 6.6703x - 0.1811
R² = 0.9991

40

y = 5.2969x - 1.7497
R² = 0.9815

20
y = 4.1308x + 0.2018
R² = 0.9998

0
0

1

2

3

4

5

Concentration (mM)
Figure 25: (Above) T1 relaxivities of Gd-DOTA (red), Fmoc-dTrp-Ala(Gd-DO3A)-OH (8) (blue), H-dTrpAla(Gd-DO3A)-OH (9) (yellow), and DCL-DSS-dTrp-Ala(Gd-DO3A)-OH (10) (purple), plotted against
concentration (mM) in water as measured with a 43 MHz Magritek NMR. Nonlinearity of Fmoc-dTrpAla(Gd-DO3A)-OH does not lend itself to trendline plotting and therefore relaxivity cannot not be
reported.

To ensure the results, the sample was re-purified, re-freeze dried and the solutions were
prepared a second time by Andrew O’Brien, who was following up on this finding, with nearly
identical results. (Fig. 26) While the reasons for this increase in relaxivity at the higher
concentrations are not entirely clear at this time, there are a few speculations that we can make.
First, Gd3+ when not in chelation has a very high T1 relaxivity. There is a possibility of Gd
partially dissociating from its coordination complex as the concentration of the CA increases. This
would be observed as a non-linear increase in relaxivity as concentration increases. However,
when the sample was retrieved and tested by LC-MS, no de-metallation had resulted.
Furthermore, if demetallation were occurring, we think similar non-linear increases would also be
seen in the other complexes containing Trp-Ala(Gd-DO3A)-OH as well, but this was not observed
in the data points of the other compounds which followed a linear trend.
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6

In another aspect, it is important to recognize that this unusual effect with high relaxivity at
higher concentrations, and with normal relaxivity at lower concentrations only occurred in the one
case where two aromatic ring systems were in proximity to each other. The examples where the
single tryptophan or single fluorine group were present did not yield this effect. We therefore
speculate further that the curve might be bi-phasic (as shown in Figure 26) due to an effect such as
aggregation caused by pi-stacking which requires the presence of at least two aromatic rings.48
However, such speculation clearly requires more data points from this compound, and additional
results from additional compounds in order to firm up the theory.

T1 Relaxivity vs Concentration of Fmoc-dTrp-Ala(Gd-DO3A)-OH

Figure 26: (Above) Third set of T1 relaxivity data of F-dTrp-Ala(Gd-DO3A)-OH (8) where r1 = 16.63 ±
3.08 mM-1s-1. (Data was acquired by Andrew O’Brien.)

In summary, while the exact mechanism and factors which give rise to this non-linear trend
are not clear, this unexpected finding represents an opportunity for future students to investigate
the origin of the effect and possibly exploit in developing a method to prepare true high-relaxivity
agents across all concentrations. It can be said, however, that a high relaxivity agent has been
prepared in compound 8, though only at concentrations above 2 mM, and lays the groundwork for
future advances in the design of high-relaxivity agents for MRI.
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Conclusions
A new method for the synthesis of high-relaxivity compounds based on the alanine
approach by Boros has been developed.35 The result is a total synthesis of the targeted molecular
imaging agent (TMIA), also called high relaxivity targeted contrast agent (HR-TCA) from a readily
purchased precursor, Cbz-Ser(H)-OBn. The modular approach dispenses with the t-butyl
protecting groups described in the literature and replaces them with the Gd metal which also serves
as a protecting group in addition to its role as a contrast agent.
The synthesis involves the further insertion of tryptophan to add lipophilicity, a UV handle
for use in diode array detection, to slow down the compound on C18 silica during purification, to
increase bioavailability and cell permeation and, as hypothesized, to boost the T1 relaxivity. In the
final steps, the resulting imaging module H-Trp-Ala(Gd-DO3A)-OH is coupled in a convergent
step with the targeting module DCL-DSS to afford the final HR-TCA, DCL-DSS-Trp-Ala(GdDO3A)-OH (10).
While the measured T1 relaxivity of the final HR-TCA DCL-DSS-Trp-Ala(Gd-DO3A)OH (10) was somewhat disappointing as it was not quite high enough to firmly be considered highrelaxivity, the successful synthesis of imaging module H-Trp-Ala(Gd-DO3A)-OH (9) could still
provide high relaxivity in agents that contained additional structural features which we hypothesize
were present in the larger peptides prepared by Boros, et al. 35 As the prior literature clearly
indicates that Ala(Gd-DO3A) can provide high relaxivity in larger peptides, our synthesis, which
involved extensive optimization of each step, paves the way for its incorporation into future
TMIAs.
In a surprising finding, it was discovered that the intermediate, Fmoc-dTrp-Ala(GdDO3A)-OH (8) did exhibit high T1 relaxivity in our measurements. It is hypothesized that the
addition of aromatic moieties, such as an extra aromatic residue or Fmoc group on an adjacent
amino acid, that such structural modifications could indeed lead to CAs of much higher T1
relaxivity. Thus, this presents an opportunity for future students to investigate the exact
mechanisms and factors responsible this trend in our data, and to further develop true highrelaxivity agents for MRI.
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Experimental Procedures
General Considerations
Chemicals were HPLC or American Chemical Society grade and were purchased from
VWR (Radnor, PA), Sigma Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), TCI (Tokyo,
Japan), and Acros Organics (Morris Plains, NY), and, unless stated otherwise, were used as
received. Amino acid starting materials were purchased from Bachem (Bubendorf, Switzerland),
and Ambeed. (Arlington Heights, IL). DOTA was purchased from Macrocyclics (Houston, TX).
The HPLC-MS instrument used was a Waters 2695 Alliance HPLC with a Waters 2998
Diode Array Detector and a Waters 3100 SQ Mass Spectrometer. HPLC columns used were an
Agilent XDB C18 column (3 mm x 100 mm, 3μ) and a Waters XBridge C18 column (50 mm x 3
mm, 3μ). Mass spectra were recorded at unit resolution with positive and negative switching mode
at 35 V cone voltages. HPLC was configured with 0.5 mL/min flow rate and solvent system of
ACN in 0.1 M ammonium acetate aqueous phase.
Flash HPLC instrument was run on a Biotage Selekt with a Biotage Sfär C18 30g column,
configured with a flow rate of 25 mL/min, and fraction collection volume of 20 mL. Fractions were
collected in 16 x 150 mm test tubes.
Data for high resolution mass spectra (HRMS) was outsourced to the School of Chemical
Sciences at the University of Illinois at Urbana-Champaign. Samples were run on a Waters Synapt
G2Si using the following parameters: Flow injection at flow rate of 0.1 mL/min, H2O/ACN/0.1%
Formic Acid, positive and negative mode ESI, Cone voltage = 25, capillary voltage = 3.0, ion
source temperature = - 100°C, desolation temperature = 180°C, nebulizing gas (N 2) flow = 200 L/h,
cone gas (N2) flow = 5 L/h.

Cbz-Ser(Ms)-OBn (2)
Mesylation of the commercially available Cbz-Ser(H)-OBn starting material (1) (5.0 g,
15.18 μmol) was run for 30 minutes under argon gas at 0°C with Ms-Cl (1.2 eq) and TEA (1.6 eq)
in DCM solvent. Crude reaction was extracted with DCM and deionized H2O. Organic phase was
rotary evaporated and dried with MgSO4 overnight. The dried organic phase was filtered to remove
the MgSO4, dried in vacuo, then put under high vacuum overnight to obtain Cbz-Ser(Ms)-OBn (2)
in excellent yield (>98%) and purity (>90%).
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Cbz-Ala(Cyclen)-OBn (3)
Cbz-Ser(Ms)-OBn (2) (1.81 g, 4.44 μmol) was dissolved in ACN with 1.5 eq of K2CO3. The
mixture was heated to 65°C and cyclen (4 eq) was added and allowed to react overnight. After
filtering off the K2CO3 and concentrating the crude reaction in vacuo, a liquid-liquid back
extraction was performed with EtOAC as the organic phase, two washes of deionized water, and a
final wash with half saturated brine. The resulting washed organic phase was dried under MgSO4
overnight, filtered, and then rotary evaporated to get rid of the bulk of the solvent. The remaining
sticky residue was placed over high vacuum overnight. Cbz-Ala(Cyclen)-OBn (3) was obtained in
82% yield and approximately 85% purity.

Cbz-Ala(DO3A-tBu3)-OBn (4)
Cbz-Ala(Cyclen)-OBn (3) (0.405 g, 8.4 μmol) was dissolved in acetone with K2CO3 (1.5 eq).
Tert-butyl bromoacetate (3.2 eq) was added to the mixture and reacted for 16 hours at room
temperature. Upon completion, the K2CO3 was filtered off and the remaining liquid was rotary
evaporated as much as possible. The resulting residue underwent liquid-liquid extraction by
dissolving it into EtOAc and washing once with deionized water followed by saturated brine. The
organic layer was dried under MgSO4 overnight, filtered, and rotary evaporated to remove all
solvent. The thick, sticky residue was then dried over high vacuum overnight to afford CbzAla(DO3A-tBu3)-OBn (4) at 75% yield and approximately 80% purity. LC-MS (LR, ESI) = Calcd.
for C44H67N5O10 MW 827.05; Found 827.27 [M+H]+.

Cbz-Ala(DO3A)-OBn (5)
Cbz-Ala(DO3A-tBu3)-OBn (4) (3.70 g, 44.82 μmol) was dissolved in pure TFA (25 mL),
and TIPS (2 eq, 1.83 mL, 8.96 μmol) was immediately added as a radical scavenger before
allowing to react for a maximum of 4-5 hours at room temperature. TFA was thoroughly removed

in vacuo with multiple washes of ACN. The resulting residue, crude compound 5, was purified
with reverse phase HPLC. Pure fractions were concentrated in vacuo and freeze dried overnight to
obtain Cbz-Ala(DO3A)-OBn (5) at a final yields of 12.9-24.74% but near immaculate purity. LCMS (LR, ESI) = Calcd. for C32H43N5O10 MW 658.73, Found 658.14 [M+H]+. HRMS (HR, ESI) =
657.3010, Found 658.3090 [M+H]+.
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Cbz-Ala(Gd-DO3A)-OBn (6)
Cbz-Ala(DO3A)-OBn (5) (0.140 g, 0.64 μmol) was dissolved in 5 mL of 15% ACN in
5mM AmAc buffer and combined with 3 eq of Gd(OAc)3 (0.214 g, 0.639 μmol). Mixture was
allowed to stir for 15-30 min to obtain crude Cbz-Ala(Gd-DO3A)-OBn (6). Flash chromatography
of crude compound 6 was run on C18 silica using gradients of ACN in 5mM AmAc buffer starting
at 10% and increasing by increments of 10 up to 50%. The pure fractions were concentrated in

vacuo and freeze dried overnight to afford purified compound 6. LC-MS (LR, ESI) = Calcd. for
C32H40GdN5O10 MW 812.96, Found 813.03 [M+H]+, 1217.96 [3M+2H]2+, 1625.12 [2M+H]+.

H-Ala(Gd-DO3A)-OH (7)
Cbz-Ala(Gd-DO3A)-OBn (6) (0.113 g, 0.139 μmol) was combined with Palladium Black (1
eq, 0.21 μmol) in methanol and allowed to react for 3 hours while H2 gas was bubbled into the
reaction. Filtration of as much catalyst as possible, concentration of the reaction in vacuo, and
freeze drying the resulting residue yielded H-Ala(Gd-DO3A)-OH (7) at >100% yield. HRMS (HR,
ESI-) = Calcd. for C17H28GdN5O8 MW 586.6821, Found 587.11 [M-H]-.

Fmoc-Trp-Ala(Gd-DO3A)-OH (8)
To synthesize Fmoc-Trp-Ala(Gd-DO3A)-OH (8), commercially available Fmoc-Trp-OH
(1 eq, 0.0936 g, 0.159 μmol) was first activated with DIPEA (20 eq, 0.55 mL, 0.00318 μmol) and
coupling agent TSTU (2 eq) in DMF solvent. In a separate flask, H-Ala(Gd-DO3A)-OH (7) was
combined with just enough DMF to dissolve with 20 eq of DIPEA (0.55 mL, 0.00318 μmol). Prior
combining the two mixtures, a small aliquot (~1-2 drops) of the activated Fmoc-Trp-Ala was
crashed out of solution with diethyl ether, vortexed, and centrifuged. The supernatant was
decanted while the remaining solids were dried under Ar (g) then combined with ~0.1% aqueous
octylamine for HPLC to double check that the Fmoc-Trp-OH had properly been activated. Once
activation of all Fmoc-Trp-OH was confirmed, the mixture of H-Ala(Gd-DO3A)-OH (7) and
DIPEA was added and sealed under Ar(g) to react overnight in the fridge. Upon reaction
completion, approximately half the DMF was removed in vacuo and combined diethyl ether to
crash the product out of solution, vortexed, and then centrifuged. The supernatant was separated
from the solids which were dried under Ar (g) to obtain crude Fmoc-Trp-Ala(Gd-DO3A)-OH (8).
This was then put through C18 SPE with a gradient of 20%-50% ACN. The pure fractions were
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collected, combined, and concentrated in vacuo, then freeze dried overnight to afford compound
8, Fmoc-Trp-Ala(Gd-DO3A)-OH, at ~37% yield and ~75% purity. HRMS (HR, ESI-) = Calcd. for
C43H50GdN7O11 MW 995.1551, Found 995.2567 [M-H]-.

H-Trp-Ala(Gd-DO3A)-OH (9)
Fmoc-Trp-Ala(Gd-DO3A)-OH (8) (0.0544 g, 0.055 μmol) was combined with 12.9 mL of
DEA (24 eq, 1.311 μmol) in DMF and allowed to react for 2 hours. Upon completion, half of the
solvent was removed in vacuo. The remaining residue was combined with diethyl ether to crash
out the product which was then vortexed and centrifuged to separate the precipitate and
supernatant. The precipitate was dried under Ar (g) to remove of any remaining diethyl ether and
then dried under vacuum overnight to afford H-Trp-Ala(Gd-DO3A)-OH (9) at 77.78% yield.
HRMS (HR, ESI-) = Calcd. for C28H38N7O9 773.1915 MW, Found 773.1897 [M-H]-.

DCL-DSS-Trp-Ala(Gd-DO3A)-OH (10)
To synthesize DCL-DSS-Trp-Ala(Gd-DO3A)-OH (10), H-Trp-Ala(Gd-DO3A)-OH (9)
(0.010 g, 0.011 μmol) was combined with TEA (16 eq) in DMF. Once dissolved, in-house made
targeting group with attached linker, DCL-DSS (1 eq, 0.0065 g, 0.011 μmol), was dissolved into the
mixture. The reaction was sealed under Ar(g) and allowed to react overnight in the freezer. When
completed, half of the DMF was removed in vacuo and product precipitated with diethyl ether.
The mixture was then vortexed and centrifuged to remove the supernatant. The remaining
precipitate was put through C18 SPE with 2%-30% Methanol gradient increasing in 2% increments.
Pure fractions were combined and concentrated in vacuo, then freeze dried overnight to afford
DCL-DSS-Trp-Ala(Gd-DO3A)-OH (10), the final HR-TCA, at 60.4% yield. LC-MS (LR, ESI) =
1232.39, Found 1231.88 [M-H]-, 616.39 [M+2H]2+. HRMS (HR, ESI-) = Calcd. for C48H69GdN10O18
MW 1230.3761, Found 1230.3960 [M-H]-, 1212.3835 [M-H2O-H]-, 1252.3762 [M+Na-2H]-.
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Appendix I – HPLC-MS and HRMS Data
Compound 4: Cbz-Ala(DO3A-tBu3)-OBn

Positive ion LR mass spectra of Cbz-Ala(DO3A-tBu3)-OBn (4) with parent ion [M+H]+ at 827.27 m/z.

Compound 5: Cbz-Ala(DO3A)-OBn

Positive ion mass spectra of Cbz-Ala(DO3A)-OH (5) (658.14 m/z) with acetal byproduct 4b or hemiacetal
byproduct 4c (Scheme 3) at 716.06 m/z. A small peak representing the sodium adduct is seen at 680 m/z. Trace
amounts of starting material where only one t-butyl has been removed can be seen at 773 m/z.
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HRMS in positive ion mode of Cbz-Ala(DO3A)-OH (5) (658.3090 m/z). Mass at 568.2623 m/z is speculated to be
fragmentation loss of the Bn protecting group, and 524.2724 m/z is speculated to be further loss of carbon dioxide
from the C-terminal backbone in the instrument.

Compound 6: Cbz-Ala(Gd-DO3A)-OBn
[M+H]+

[3M+2H]2+
((812*3)+2)/2
[2M+H]
+

Positive ion LR mass spectra of a fraction from the reverse phase SPE purification Cbz-Ala(Gd-DO3A)-OBn (6)
(813.03 m/z). Multiply charged cluster [3M+2H] can be seen at 1217.96 m/z, as well as the mass spec dimer [2M+H]
at 1625.12 m/z.
2+

+
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Positive ion LR mass spectra of the peaks at 1.39 (top) and 4.23 (bottom) retention time showing the hydrolyzed
product (723.20 m/z, loss of benzyl) and Cbz-Ala(Gd-DO3A)-OBn (6) (813.18 m/z), respectively.

Extracted positive ion chromatograms of compound 6 where the Bn protecting group has been hydrolyzed to form
Cbz-Ala(Gd-DO3A)-OH (top) and full in-tact product (middle) alongside the total ion chromatogram (bottom).
Difference in retention time suggests the hydrolytic cleavage of Bn occurs outside the mass spectrometer and is
therefore not the result of a fragmentation reaction inside the instrument.
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Gd isotope patterns of the hydrolyzed Cbz-Ala(Gd-DO3A)-OH (6) (left) and full intact product (right) confirming
presence of Gd in the final, freeze-dried materials.

Purified Hydrolyzed Cbz-Ala(Gd-DO3A)-OBn (6) appears as white tiny crystals.
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Compound 7: H-Ala(Gd-DO3A)-OH
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HRMS in negative ionization mode of H-Ala(Gd-DO3A)-OH (7) at 587.1107 m/z.

43

1600

1700

1800

1900

Ha ns S chmitthe nne r

1029-05

MSL, S chool of Che mica l S cie nce s , UIUC

S YNAP TG2-S i#NotS e t

S yna pt2_15077n1 17 (0.364) Cm (17:24-41:46x2.000)

1: TOF MS ES 4.75e 4

587.1107

100

585.1083

589.1134

586.1110

%

584.1097

588.1152
590.1188
583.1032
577.0917

595.1320

599.1183

0

m/z
574

576

578

580

582

584

586

588

590

592

594

596

598

600

602

Gd Isotope pattern in negative ion mode of high-resolution mass spectra of H-Ala(Gd-DO3A)-OH (7).
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Compound 8: Fmoc-dTrp-Ala(Gd-DO3A)-OH
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Compound 9: H-dTrp-Ala(Gd-DO3A)-OH
Ha ns S chmitthe nne r

1029-03

MSL, S chool of Che mica l S cie nce s , UIUC

S yna pt2_15075n 22 (0.448) Cm (17:22-3:7x2.000)
773.1897

100

S YNAP TG2-S i#NotS e t

[M-H]-

1: TOF MS ES 5.21e 4

771.1874 775.1921

%

681.2950

776.1940
265.1471

873.1152

447.1323
290.8878

162.8426

875.1142

491.3037

876.1110 1017.0543

1203.0190

1402.2789

1871.9681

1550.6582

1972.9644

0

m/z
100

200

300

400

500

600

700

800

900

1000

1100

1200

1300

1400

1500

1600

1700

1800

1900

HRMS in negative ionization mode of H-dTrp-Ala(Gd-DO3A)-OH (9) (773.1897 m/z) in negative ion mode.
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Gd isotope pattern of HRMS of H-dTrp-Ala(Gd-DO3A)-OH (9) in negative ion mode.
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HRMS in negative ionization mode of DCL-DSS-dTrp-Ala(Gd-DO3A)-OH (10) (1230.3960 m/z).
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Positive ion LR mass spectra of pure fraction from SPE purification of DCL-DSS-dTrp-Ala(Gd-DO3A)-OH (10).
Both the full and half mass can be seen at 1231.88 m/z and 616.39 m/z, respectively.
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DCL-DSS-dTrp-Ala(Gd-DO3A)-OH (10) freeze drying on a vacuum manifold.
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DSS-Trp-Ala(Gd-DO3A)-OH
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HRMS of alternative synthetic route intermediate DSS-Trp-Ala(Gd-DO3A)-OH in negative ion mode.

51

1900

Ha ns S chmitthe nne r

1029-02

MSL, S chool of Che mica l S cie nce s , UIUC

S YNAP TG2-S i#NotS e t

S yna pt2_15074N3 19 (0.397) Cm (18:22-(4:7+38:40)x2.000)

1: TOF MS ES 2.07e 5

906.6149

100

747.5642

681.2949

%

907.6177

748.5662

1016.7225

687.5427

860.6080
1017.7258
908.6225

749.5719

804.5742

861.6109

688.5463
750.5516 802.5593

1014.7074

830.5908
857.6713

722.5120

862.6135

970.7181
971.7130

927.2667

1018.7306

0

m/z
625

650

675

700

725

750

775

800

825

850

875

900

925

950

975

1000

1025

1050

1075

Zoomed in HRMS of alternative synthetic route intermediate DSS-Trp-Ala(Gd-DO3A)-OH in negative ion mode.
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T1 Relaxivity Data
T1 Relaxivity of Gd-DOTA vs. Concentration (mM)
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T relaxivity of Fmoc-dTrp-Ala(Gd-DO3A)-OH (8) plotted against concentration (mM). Fmoc-dTrp-Ala(Gd-DO3A)OH (8) was found to have a relaxivity value of 21.528 mM s .
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T1 Relaxivity of H-dTrp-Ala(Gd-DO3A)-OH vs Concentration
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T relaxivity of H-dTrp-Ala(Gd-DO3A)-OH (9) plotted against concentration (mM) was 6.0623 mM s .
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T relaxivity of DCL-DSS-dTrp-Ala(Gd-DO3A)-OH (10) plotted against concentration (mM) as measured with 43
MHz Magritek NMR Spectrometer. DCL-DSS-dTrp-Ala(Gd-DO3A)-OH (10) was found to have a T relaxivity value
of 6.6703 mM s .
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T1 Relaxivity vs Concentration
Gd-DOTA
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T relaxivities of Gd-DOTA (red), Fmoc-dTrp-Ala(Gd-DO3A)-OH (8) (blue), H-dTrp-Ala(Gd-DO3A)-OH (9) (gold),
and DCL-DSS-Trp-Ala(Gd-DO3A)-OH (10) (purple), plotted against concentration (mM) as measured with a 43
MHz Magritek NMR.
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